AMG 510 is in clinical development for the treatment of adults with KRASG12C mutated, metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer and a small proportion of patients with NSCLC have tumours which carry the genetic mutation KRASG12C. Metastatic NSCLC describes tumours that have spread from the lungs to other parts of the body. Current NSCLC treatment depends largely on the stage of the cancer and any genetic mutations identified in the tumours and can include surgery, chemotherapy, radiotherapy, targeted cancer drugs and immunotherapy. Despite a wide range of treatments being available for lung cancers, there are currently no approved treatments for KRASG12C mutated, metastatic NSCLC.
AMG 510 is a small molecule which binds to a site on the protein KRAS and locks it in an inactive state. This blocks signals between tumour cells and stops further growth. AMG 510 is the first molecule which has been able to target the protein KRAS effectively. It is given as an oral tablet and is intended to be used following prior standard therapy for NSCLC. If licensed AMG 510, has the potential to be the first available treatment targeted for patients with KRASG12C mutated NSCLC.
Pembrolizumab is an immunomodulatory medicinal product, meaning that it helps the immune system to recognise and attack cancer cells. It is administered by intravenous infusion and is currently licensed in the UK for melanoma, non-small cell lung cancer and urothelial cancer – amongst others. If licensed, pembrolizumab, in addition to chemotherapy, would offer an alternative treatment for those with advanced, recurrent or metastatic cervical cancer.